Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor.

Inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1) have shown to be promising in clinical trials against cancer and other diseases, and lots of efforts have been put into the development of organic compounds as more potent PARP-1 inhibitors. Here we describe a strategy to conveniently obtain metal-based PARP-1 inhibitors with enhanced biological activities by conjugating platinum moiety with an original inhibitor, e.g., benzonaphthyridone. Based on the structure-activity relationship analysis of PARP-1 inhibitors, three platinated PARP-1 inhibitors were designed, and the complexes were synthesized and characterized. Complex 3 presented significantly enhanced cytotoxicity against a panel of human cancer cells and a 10-fold increased inhibitory effect against recombinant PARP-1 compared with the original PARP-1 inhibitor. Complex 3 was as cytotoxic as cisplatin and its spectrum of anticancer activity was identical to that of cisplatin. The complex was able to enter into cancer cells efficiently, bind to DNA well, and block cell cycle at G₂/M phase, indicating that complex 3 is an effective anticancer agent with a distinct mechanism of action. Our study implies that the conjugation of platinum with PARP-1 inhibitors could be a valid strategy to obtain more potent anticancer agents with improved biological activities.
AuthorsBeilei Wang, Hui Qian, Shek-Man Yiu, Jianwei Sun, Guangyu Zhu
JournalEuropean journal of medicinal chemistry (Eur J Med Chem) Vol. 71 Pg. 366-73 (Jan 2014) ISSN: 1768-3254 [Electronic] France
PMID24361480 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 Elsevier Masson SAS. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Naphthyridines
  • Organoplatinum Compounds
  • Poly(ADP-ribose) Polymerase Inhibitors
  • benzonaphthyridone
  • PARP1 protein, human
  • Poly(ADP-ribose) Polymerases
  • Cisplatin
  • Antineoplastic Agents (chemistry, pharmacology)
  • Cell Cycle (drug effects)
  • Cell Line, Tumor
  • Cisplatin (pharmacology)
  • Enzyme Inhibitors (chemistry, pharmacology)
  • Humans
  • Naphthyridines (chemistry, pharmacology)
  • Neoplasms (drug therapy, enzymology)
  • Organoplatinum Compounds (chemistry, pharmacology)
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Poly(ADP-ribose) Polymerases (metabolism)
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: